Pfizer says late-stage trial data shows Covid vaccine is more than 90% effective

LongIsland.com

Pfizer says late-stage trial data shows Covid vaccine is more than 90% effective in preventing infection

Print Email

According to data published this morning, U.S. pharmaceutical Pfizer and German biotech firm  BioNTech say their coronavirus vaccine was more than 90% effective in preventing COVID-19.

The analysis evaluated 94 confirmed Covid-19 infections among the trial’s 43,538 participants. Pfizer and BioNTech said the case split between vaccinated individuals and those who received a placebo indicated a vaccine efficacy rate of above 90% at seven days after the second dose.
 
It means that protection from Covid-19 is achieved 28 days after the initial vaccination, which consists of a two-dose schedule.